Literature DB >> 26059706

SGLT-2 inhibition and glucagon: Cause for alarm?

Richard G Kibbey1.   

Abstract

Recent studies raised the alarm that the inhibition of sodium-coupled glucose transporter type-2 in humans increases endogenous glucose production rates by an unclear mechanism. Surprisingly, a potential explanation may be linked directly to the alpha-cell. Is this a mechanistic spoiler or an added benefit?
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  HNF4alpha; SGLT-2 inhibitors; alpha-cell; glucagon; glucose production

Mesh：

Substances：

Year:  2015        PMID： 26059706      PMCID： PMC4490128          DOI： 10.1016/j.tem.2015.05.011

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN： 1043-2760            Impact factor:   12.015


  10 in total

1.  Metabolic adaptation to experimentally increased glucose demand in ruminants.

Authors:  T R Overton; J K Drackley; C J Ottemann-Abbamonte; A D Beaulieu; J H Clark
Journal:  J Anim Sci       Date:  1998-11       Impact factor: 3.159

2.  Sugar binding to Na+/glucose cotransporters is determined by the carboxyl-terminal half of the protein.

Authors:  M Panayotova-Heiermann; D D Loo; C T Kong; J E Lever; E M Wright
Journal:  J Biol Chem       Date:  1996-04-26       Impact factor: 5.157

3.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.

Authors:  Caroline Bonner; Julie Kerr-Conte; Valéry Gmyr; Gurvan Queniat; Ericka Moerman; Julien Thévenet; Cédric Beaucamps; Nathalie Delalleau; Iuliana Popescu; Willy J Malaisse; Abdullah Sener; Benoit Deprez; Amar Abderrahmani; Bart Staels; François Pattou
Journal:  Nat Med       Date:  2015-04-20       Impact factor: 53.440

4.  AICAR and phlorizin reverse the hypoglycemia-specific defect in glucagon secretion in the diabetic BB rat.

Authors:  R J McCrimmon; M L Evans; R J Jacob; X Fan; Y Zhu; G I Shulman; R S Sherwin
Journal:  Am J Physiol Endocrinol Metab       Date:  2002-11       Impact factor: 4.310

5.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

Authors:  Ele Ferrannini; Elza Muscelli; Silvia Frascerra; Simona Baldi; Andrea Mari; Tim Heise; Uli C Broedl; Hans-Juergen Woerle
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

6.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.

Authors:  Aurora Merovci; Carolina Solis-Herrera; Giuseppe Daniele; Roy Eldor; Teresa Vanessa Fiorentino; Devjit Tripathy; Juan Xiong; Zandra Perez; Luke Norton; Muhammad A Abdul-Ghani; Ralph A DeFronzo
Journal:  J Clin Invest       Date:  2014-01-27       Impact factor: 14.808

7.  Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization.

Authors:  H Heimberg; A De Vos; D Pipeleers; B Thorens; F Schuit
Journal:  J Biol Chem       Date:  1995-04-14       Impact factor: 5.157

8.  Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes.

Authors:  A Starke; S Grundy; J D McGarry; R H Unger
Journal:  Proc Natl Acad Sci U S A       Date:  1985-03       Impact factor: 11.205

9.  SGLT2 deletion improves glucose homeostasis and preserves pancreatic beta-cell function.

Authors:  Michael J Jurczak; Hui-Young Lee; Andreas L Birkenfeld; Francois R Jornayvaz; David W Frederick; Rebecca L Pongratz; Xiaoxian Zhao; Gilbert W Moeckel; Varman T Samuel; Jean M Whaley; Gerald I Shulman; Richard G Kibbey
Journal:  Diabetes       Date:  2011-03       Impact factor: 9.461

10.  In vitro reprogramming of pancreatic alpha cells towards a beta cell phenotype following ectopic HNF4α expression.

Authors:  Caroline B Sangan; Ramiro Jover; Harry Heimberg; David Tosh
Journal:  Mol Cell Endocrinol       Date:  2014-09-16       Impact factor: 4.102
  10 in total
  16 in total

1.  Euglycemic diabetic ketoacidosis in type 2 diabetes treated with a sodium-glucose cotransporter-2 inhibitor.

Authors:  Mazen Jazi; George Porfiris
Journal:  Can Fam Physician       Date:  2016-09       Impact factor: 3.275

2.  [L'acidocétose euglycémique dans le diabète de type 2 traité avec un inhibiteur du cotransporteur sodium-glucose de type 2].

Authors:  Mazen Jazi; George Porfiris
Journal:  Can Fam Physician       Date:  2016-09       Impact factor: 3.275

Review 3.  Direct cardiovascular impact of SGLT2 inhibitors: mechanisms and effects.

Authors:  Abdullah Kaplan; Emna Abidi; Ahmed El-Yazbi; Ali Eid; George W Booz; Fouad A Zouein
Journal:  Heart Fail Rev       Date:  2018-05       Impact factor: 4.214

Review 4.  Management of Hyperglycemic Crises: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar State.

Authors:  Maya Fayfman; Francisco J Pasquel; Guillermo E Umpierrez
Journal:  Med Clin North Am       Date:  2017-05       Impact factor: 5.456

Review 5.  Ketones: the double-edged sword of SGLT2 inhibitors?

Authors:  Beatrice C Lupsa; Richard G Kibbey; Silvio E Inzucchi
Journal:  Diabetologia       Date:  2022-10-18       Impact factor: 10.460

6.  Metabolic ketoacidosis with normal blood glucose: A rare complication of sodium-glucose cotransporter 2 inhibitors.

Authors:  Saad Ullah; Noman Khan; Hassan Zeb; Hassan Tahir
Journal:  SAGE Open Med Case Rep       Date:  2016-11-24

Review 7.  The efficacy and safety of SGLT2 inhibitors for adjunctive treatment of type 1 diabetes: a systematic review and meta-analysis.

Authors:  Jiao Chen; Fang Fan; J Y Wang; Yang Long; C L Gao; R C Stanton; Yong Xu
Journal:  Sci Rep       Date:  2017-03-09       Impact factor: 4.379

8.  Sodium-glucose Cotransporter-2 Induced Diabetic Ketoacidosis with Minimal Hyperglycemia.

Authors:  D Taylor Gammons; Francis L Counselman
Journal:  Clin Pract Cases Emerg Med       Date:  2018-01-11

Review 9.  Pancreatic β Cell Mass Death.

Authors:  Husnia I Marrif; Salma I Al-Sunousi
Journal:  Front Pharmacol       Date:  2016-04-06       Impact factor: 5.810

10.  Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors.

Authors:  Wataru Ogawa; Kazuhiko Sakaguchi
Journal:  J Diabetes Investig       Date:  2015-09-06       Impact factor: 4.232
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.